73 results about "Chemo-radiotherapy" patented technology

The invention relates to a double-cavity radiotherapy and chemotherapy integrated treatment capsule for brain glioma, which aims to solve the problems that the existing radioactive seed source or chemotherapy carrier cannot give consideration to radiotherapy and chemotherapy, the dosage is difficult to regulate and control, the medicine distribution is non-uniform and the like. The brain glioma double-cavity radiotherapy and chemotherapy integrated treatment bag is composed of a radiotherapy pipeline and a chemotherapy pipeline, the whole integrated treatment bag is a spiral pipe body, the radiotherapy pipeline is located in an inner ring, the chemotherapy pipeline is located in an outer ring, the radiotherapy pipeline is a closed cavity, a liquid radioactive source is contained in the closed cavity, and the liquid radioactive source is located in an outer ring. The chemotherapy medicine is released from the head end of the chemotherapy pipeline, the chemotherapy medicine is injected from the tail end of the chemotherapy pipeline, and the surface of the integrated treatment bag is coated with a composite antibacterial layer. According to the integrated treatment capsule, radiopharmaceuticals and chemical drugs are placed in the inner cavity and the outer cavity respectively, synergistic treatment of radiotherapy and chemotherapy is achieved through the synchronous effect of the two channels, and long-term low-dose release of the radiopharmaceuticals and the chemotherapy drugs is achieved and toxic and side effects are reduced by adjusting the screw pitch and the thickness of the tube wall.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine electuary for intestinal injury caused by radiotherapy and chemotherapy and a preparation method of the traditional Chinese medicine electuary. According to the composition principle of monarch, minister, assistant and guide of a traditional Chinese medicine prescription, the traditional Chinese medicine electuary is prepared by taking radix astragali preparata as a monarch drug, taking radix codonopsis and rhizoma polygonati as minister drugs, and taking poria cocos, bran-fried rhizoma atractylodis macrocephalae, hairyvein agrimony, Chinese pulsatilla root, rhizoma bletillae and pinellia ternate as assistant drugs, and taking pericarpium citri reticulatae, vinegar-processed curcuma zedoary, pseudo-ginseng and musk as assistant drugs through scientific compatibility and a preparation process. The intestinal function can be adjusted, and the intestinal injury symptom caused by radiotherapy and chemotherapy is improved.

The application provides a preparation method of high-selenium compound powder for postoperative and radiotherapy rehabilitation immune repair, and belongs to the technical field of functional food or special medical use formula food processing technology.The application realizes sufficient wall breaking by respectively pre-wetting and low-temperature complex enzymolysis of hard plant wall and fungal wall raw materials, and then prevents active loss by using endogenous substances of the raw materials for in-situ anchoring without adding, after drying and crushing, adding postbiotic powder, active peptide, whey protein, yeast beta-glucan, EGCG and other heat-sensitive components into low-temperature sterile dry mixing, while maximizing the release of organic selenium and immune active substances, the heat-sensitive functional components are completely protected from degradation and inactivation, and finally the technical target of sufficient wall breaking, complete activity and stable immune repair effect is achieved.The product prepared by the application can improve the immune organ damage and immune homeostasis imbalance caused by radiotherapy, and is suitable for the immune repair of postoperative and radiotherapy rehabilitation population.

The invention relates to the technical field of virtual reality medical treatment, and discloses a head and neck cancer chemoradiotherapy related symptom remote monitoring and multi-sensory intervention method based on VR, and the method comprises the following steps: S1, a patient carries out preliminary evaluation through a first input module of a VR terminal, and transmits monitoring data to a data processing module through the VR terminal; s2, performing secondary evaluation on the average score or the symptom of which any score is in a second interval in a targeted manner through a first input module of the VR end, and sending a multi-sensory first-level intervention request or a multi-sensory second-level intervention request or a multi-sensory third-level intervention request to the VR end by a data processing module according to the score condition of the symptom; and S3, after the patient completes corresponding intervention, performing post-intervention evaluation through the first input module of the VR end, and comparing the evaluation conditions before and after intervention by the data processing module to generate an intervention effect evaluation report. Related symptoms of a patient can be dynamically monitored in real time, symptom changes can be found in time, corresponding intervention is given, treatment interruption is prevented, and the lifetime is prolonged.

The invention relates to the technical field of medical information systems, in particular to a nursing system for tumor patients in a chemoradiotherapy period, which comprises a physiological monitoring module, a threshold evaluation module, a path switching module, a task decomposition module and a nursing scheduling module. According to the method, by continuously collecting multi-dimensional physiological data such as the heart rate, the blood oxygen saturation degree, the blood pressure and the serum creatinine of the patient and conducting noise suppression processing, stable bearing state information can be obtained, and dynamic quantitative evaluation of the tolerance degree is achieved in combination with deviation analysis of the nursing base line; the nursing task is subjected to priority and rhythm adjustment when the bearing index exceeds the limit, the high-load task is split by utilizing fluctuation prediction, and the interval duration is set, so that the risk caused by physiological burden concentration is reduced, the nursing execution rhythm matched with the real-time state of a patient is formed, and the flexibility of load distribution and the instantaneity of intervention response are realized. And the accuracy and safety of whole-course nursing are improved.

This invention belongs to the field of tumor treatment, specifically relating to the application of a CHK1 inhibitor in the preparation of drugs that weaken radiotherapy and chemotherapy resistance in nasopharyngeal carcinoma. This invention is the first to clearly demonstrate that F-circRM mediates radiotherapy and chemotherapy resistance by activating the CHK1 signaling pathway, enhancing the DNA damage repair capacity of nasopharyngeal carcinoma cells, and thus mediating the core mechanism. The CHK1 inhibitor can effectively block this pathway, significantly enhancing the sensitivity of nasopharyngeal carcinoma to radiotherapy and chemotherapy and reversing radiotherapy and chemotherapy resistance in in vitro multi-cell lines, patient-derived primary cells, and in vivo animal models. This invention also clarifies that F-circRM can serve as a biomarker for predicting the efficacy of radiotherapy and chemotherapy, providing a basis for stratification and individualized treatment plans for nasopharyngeal carcinoma patients, and has significant clinical value and broad application prospects.

The invention discloses mouthwash for treating oral ulcer caused by chemoradiotherapy, which is mainly prepared from the following raw materials in percentage by weight: 0.15 percent to 0.25 percent of chlorhexidine gluconate, 0.015 percent to 0.025 percent of polypeptide of which the amino acid sequence is RWRWRW, 0.05 percent to 0.15 percent of sodium hyaluronate, 0.05 percent to 0.15 percent of menthol, 2.8 percent to 3.2 percent of humectant, 0.45 percent to 0.55 percent of sodium ascorbyl phosphate, 0.5 percent to 1 percent of sodium bicarbonate and the balance of distilled water. The mouthwash for treating the oral ulcer caused by the chemoradiotherapy not only has antibacterial and moisturizing functions, but also can relieve the pain degree of the oral ulcer caused by the chemoradiotherapy, reduce the infection risk and promote ulcer healing, the technical problem that an existing product is single in function is solved, a patient does not need to alternately use multiple preparations, and the compliance is high.

This application relates to the technical field of traditional Chinese medicine compositions, specifically disclosing a traditional Chinese medicine composition for treating deficiency syndromes caused by illness, surgery, radiotherapy, and chemotherapy, and its preparation process. The composition comprises Ganoderma lucidum extract and ginseng powder. The preparation method of the Ganoderma lucidum extract is as follows: Step 1, pulverizing the raw material to obtain Ganoderma lucidum powder; Step 2, extraction: extracting the Ganoderma lucidum powder with a primary liquid-liquid phase solvent for 1.5-2.5 hours, adding non-oxidizing gas nano-bubble water and extracting for 0.5-1.5 hours, then adding acidic gas nano-bubble water and continuing extraction for 0.5-1.5 hours; Step 3, collection: collecting the extract, concentrating, forming a paste, and drying to obtain the Ganoderma lucidum extract; the primary liquid-liquid phase solvent includes an alcohol solution with a volume ratio of (2-5):1 and a non-polar organic solvent, with the alcohol volume percentage in the primary alcohol solution being 65-90%. The composition of this application has a higher content of Ganoderma lucidum polysaccharides and Ganoderma lucidum triterpenes.

The application relates to the field of traditional Chinese medicine, in particular to a traditional Chinese medicine compound preparation for treating solid tumors and promoting blood circulation to remove blood stasis and a preparation method and application thereof. Under the guidance of traditional Chinese medicine theory, according to the syndrome manifestations of patients with solid tumors (early, middle and late stages), the traditional Chinese medicine compound preparation prepared from the animal traditional Chinese medicines gecko, sea squirts and leeches and the plant traditional Chinese medicines notoginseng, madder, safflower and licorice in a certain proportion is used to treat patients with blood stasis syndrome of malignant tumors, can obviously improve the life quality of the patients, reduce the toxic and side effects of radiotherapy and chemotherapy, prolong the survival period of the patients and improve the symptoms of blood stasis syndrome of the patients.

The present application relates to the technical field of traditional Chinese medicine, in particular to a traditional Chinese medicine composition for reducing adverse reactions after radiotherapy and chemotherapy of tumor patients and a preparation method thereof, comprising the following components in parts by weight: Radix Bupleuri 6-9 parts, Radix Paeoniae Alba 6-9 parts, Rhizoma Atractylodis Macrocephalae 6-9 parts, Poria 6-9 parts, Angelica sinensis 6-9 parts, Zingiber officinale 3 parts, Radix Rehmanniae Recens 3-6 parts, Gardenia 3-6 parts, Radix Paeoniae Rubra 3-6 parts, Radix Paeoniae Alba 12-20 parts, Rhizoma Chuanxiong 6 parts, and Radix Glycyrrhizae 3-6 parts; the traditional Chinese medicine composition can improve the spirit and movement state of mice, and the weight and food intake of mice are obviously increased, the number of dead mice is significantly reduced, and the tumor volume and weight of mice are significantly reduced; the spleen and thymus indexes, the number of white blood cells, red blood cells and platelets in peripheral blood, and the hemoglobin content are all significantly increased; the number of bone marrow cells and the CD4 + T / CD8 + T cell ratio in peripheral blood are all significantly increased; when applied to clinical patients, the traditional Chinese medicine composition can reduce adverse reactions after radiotherapy and chemotherapy of tumor patients, and has a broad application prospect.

A method, system, device, and medium for processing symptom cluster data of head and neck cancer patients based on sentinel symptoms are disclosed. The method includes: obtaining symptom data of head and neck cancer patients during radiotherapy and chemotherapy through longitudinal surveys; processing the symptom data using exploratory factor analysis to extract several symptom clusters; performing association rule analysis on the symptom cluster data based on the Apriori algorithm, and determining the sentinel symptoms within each symptom cluster by combining the time of first symptom appearance; and constructing an intervention plan for gastrointestinal symptoms using the sentinel symptoms as intervention targets. This invention achieves accurate determination of sentinel symptoms through longitudinal survey data, combined with the Apriori algorithm and the time of first symptom appearance, and constructs intervention plans based on the MRC complex intervention framework, realizing early symptom identification and providing precise and personalized symptom management support for head and neck cancer patients.

The application discloses poplar phellinus polysaccharide SVP-1, a preparation method and application thereof, and belongs to the field of biological medicines. The poplar phellinus polysaccharide SVP-1 provided by the application has significant antitumor activity, can effectively inhibit the proliferation, invasion and migration of tumor cells, and thus blocks the malignant progression of tumors. The structure is clear, the preparation method is controllable, the stability and biological activity of the polysaccharide component are ensured, and a reliable foundation is provided for the development of antitumor drugs. The combination with radiotherapy and chemotherapy drugs can play a synergistic effect, can not only improve the sensitivity of tumors to treatment, but also reduce the toxic and side effects of radiotherapy and chemotherapy, and realizes the effect of 'attenuation and synergism'. The combined treatment strategy can significantly improve the curative effect of the existing tumor therapy, while reducing the adverse reactions, and provides a new optimization scheme for clinical tumor treatment.

This invention belongs to the field of biomedical technology, specifically relating to triptolide liposomes (TP-lipo), their combined use, and their application in the prevention and treatment of tumors. To enhance the efficacy of triptolide in the treatment and prevention of tumors such as pancreatic cancer, cervical cancer, ovarian cancer, and colorectal cancer, and to improve its bioavailability and clinical application while reducing toxicity, this invention uses HSPC, DOPS, and cholesterol as liposome components to encapsulate triptolide monomers, thus preparing TP-lipo. Experiments have shown that TP-lipo exhibits anti-tumor activity: it directly kills tumor cells and reverses the immunosuppressive microenvironment, making it a potential drug for tumor treatment. TP-lipo, when used in combination with PD-1 antibodies, or in combination with radiotherapy, chemotherapy, or surgery, demonstrates a potent and synergistic anti-tumor effect with low toxicity. Therefore, the TP-lipo of this invention provides more clinical strategies for tumor treatment.

The invention discloses an effective part for chemoradiotherapy-induced oral mucositis in traditional Chinese medicinal material white flower and a preparation process of the effective part. The effective part is identified as a flavonoid component through standard substance spectrogram comparison. Tests prove that the production process of the effective part is practical and feasible, and the total flavonoids in the finally obtained extracting solution are greater than or equal to 50%. Besides, pharmacodynamic studies show that the effective part has a remarkable bacteriostasis effect on staphylococcus aureus, escherichia coli and candida albicans, the bacteriostasis rate is larger than or equal to 80%, the effective part has a remarkable treatment effect on rat oral mucosa acute inflammation caused by chemoradiotherapy, and the application prospect of the effective part in the adaptation disease is shown.

The invention provides a tool for intelligently evaluating the dystrophy risk of a patient with nasopharyngeal carcinoma, and the tool for evaluating the specific dystrophy of nasopharyngeal carcinoma is constructed by integrating indexes such as social demographic data, physique measurement, tumor staging, chemoradiotherapy conditions, recent adverse reactions and hematology indexes, so that high-precision risk evaluation is realized. Through single-factor and multi-factor analysis, the variable weight is optimized, and the discrimination capability and stability of the model are improved. An intelligent applet based on artificial intelligence is developed, patient data are extracted, nutrition risk calculation is completed within seconds, evaluation time is shortened, and clinical working efficiency is improved. The system also has the functions of dynamic monitoring and intelligent early warning, automatically updates the evaluation result along with the treatment progress of the patient, and provides individualized intervention suggestions. The defects that a traditional nutrition evaluation tool is high in subjectivity, low in efficiency, lack of tumor specificity and low in informatization degree are overcome, and an efficient, accurate and automatic intelligent evaluation solution is provided for clinic.

The invention discloses a nutrition intervention system and method for tumor chemoradiotherapy patients. The system comprises a molecular nutrition fingerprint acquisition module, a space-time prediction modeling module, a drug-nutrition collaborative optimization module, an intestinal flora-host metabolism modeling module and an active nutrition intervention execution module. By integrating gene polymorphism, intestinal flora and metabonomics data, an individualized molecular nutrition fingerprint is constructed, a deep learning algorithm is adopted to predict the change trend of a nutrition state, a molecular docking technology is adopted to optimize a drug-nutrition synergistic effect, a flora-host metabolism model is established to predict nutrient absorption efficiency, and the nutrient absorption efficiency is improved. And precise active nutrition intervention is realized. The technical problems that in the prior art, nutrition intervention is low in accuracy, preventive intervention cannot be achieved, and medicine-nutrition interaction is neglected are solved, and individualized nutrition management based on the molecular level is achieved.

The invention discloses a nano-vesicle composition for inhibiting tumor metastasis after radiotherapy, which is characterized in that the nano-vesicle is an engineered bacterial outer membrane vesicle (OS-D), and the composition also comprises a pH responsive phospholipid modification component and a small interfering RNA (siRNA) capable of silencing CCDC25 gene expression; the siRNA is used for inhibiting formation of neutrophil Extracellular Traps (NETs) induced by radiotherapy and tumor cell migration and metastasis mediated by the NETs by blocking the interaction between the NETs and tumor cells, so that the effect of inhibiting tumor metastasis after radiotherapy is realized. The nano-vesicle composition provided by the invention can specifically block tumor metastasis mediated by neutrophil extracellular traps in a tumor microenvironment so as to enhance the effect of tumor postoperative radiotherapy and chemotherapy and effectively inhibit tumor metastasis and relapse.

The present disclosure relates to novel radiation-triggered controlled release drug compositions, and methods to make and use the radiation-triggered controlled release drug compositions. The radiation-triggered controlled drug release nanoparticle formulations may be used to achieve maximum bioavailability and minimum adverse effects of the chemo drugs in chemo radio combination therapy treatment of locally advanced solid tumors.

The invention provides a hafnium oxide-based nano-drug as well as a preparation method and application thereof, and belongs to the technical field of nano-medicines. The preparation method comprises the following steps: mixing a hafnium chloride solution and an alkali solution, and carrying out hydrothermal reaction to obtain hafnium dioxide; mixing a bovine serum albumin solution and the hafnium oxide suspension, and performing centrifugal separation to obtain BSA modified hafnium oxide; adding a doxorubicin aqueous solution into the BSA modified hafnium oxide dispersion liquid for reaction to obtain doxorubicin-loaded hafnium oxide; and adding a potassium permanganate solution into the dispersion liquid of the doxorubicin-loaded hafnium oxide, and carrying out ultrasonic treatment to obtain the hafnium oxide-based nano-drug. The hafnium oxide-based nano-drug provided by the invention is a nano-drug capable of regulating and controlling the tumor microenvironment and combining the radiotherapy and chemotherapy functions, and can significantly improve the treatment response and benefit of patients.

This invention discloses a traditional Chinese medicine composition for treating tumors and its preparation method, belonging to the field of traditional Chinese medicine technology. The composition comprises *Uncaria rhynchophylla*, *Prunella vulgaris*, *Astragalus membranaceus*, *Adenophora stricta*, *Ophiopogon japonicus*, *Fritillaria thunbergii*, *Curcuma zedoaria*, *Panax notoginseng*, *Atractylodes macrocephala* (fried), *Ligustrum lucidum*, *Eclipta prostrata*, and *Glycyrrhiza uralensis* (processed). The formula focuses on clearing heat and detoxifying, resolving phlegm and dissipating nodules, strengthening the body's resistance, and promoting blood circulation and removing blood stasis. It combines tonification and purgation, addressing both the root cause and symptoms, precisely targeting the core pathogenesis of tumors: deficiency of vital energy, phlegm accumulation, blood stasis, and toxin accumulation. It can inhibit tumor cell proliferation, dissipate masses, enhance the body's immunity, reduce adverse reactions to radiotherapy and chemotherapy, improve clinical symptoms, stabilize tumors, and delay tumor progression and recurrence / metastasis, showing promising clinical application prospects.

This invention discloses the application of total paeoniflorin in the preparation of drugs for the treatment of head and neck squamous cell carcinoma, belonging to the field of biomedical technology. Addressing the bottlenecks in current treatments for head and neck squamous cell carcinoma, such as high toxicity of radiotherapy and chemotherapy, low response rates to immunotherapy, and easy resistance to targeted drugs, this invention provides a method for preparing total paeoniflorin and a drug-loaded preparation technology based on hydrogels obtained from modified chitosan. Total paeoniflorin can dose-dependently inhibit the proliferation rate, colony formation ability, and in vitro migration ability of SCC7, FADU, and CAL27 head and neck squamous cell carcinoma cell lines, and significantly induce apoptosis. This invention utilizes the multi-target effects of total paeoniflorin to exert anti-head and neck squamous cell carcinoma effects through modulation of the tumor microenvironment and enhancement of immune surveillance. Furthermore, the loaded drug exhibits good sustained-release properties and biosafety, providing a new, highly effective, and low-toxicity strategy for the treatment of head and neck squamous cell carcinoma, and has significant clinical application value.

The invention provides a method for enhancing the tumor homing ability of TIL cells, and belongs to the technical field of biological medicine. The invention provides a method for effectively enhancing the homing ability of TIL cells, so that the chemotactic and enrichment potential of engineered TIL cell products to tumor sites is remarkably improved. The TIL cell preparation prepared on the basis of the method has higher tumor targeting performance, and a new solution is provided for overcoming the bottleneck that effector cells'reach 'tumor parts in an existing cell therapy. The effectiveness of single cell therapy is expected to be directly improved, and better cell products can be provided for synergistic combination with other therapies such as radiotherapy and chemotherapy, so that wider and more effective treatment choices are brought to patients with solid tumors.

The invention discloses a molecular marker for evaluating prognosis of laryngeal squamous cell carcinoma and application of the molecular marker, and provides a molecular marker combination capable of accurately evaluating prognosis of laryngeal squamous cell carcinoma patients, and the prognosis of the laryngeal squamous cell carcinoma patients can be evaluated by detecting variation conditions of NOTCH1 genes, CCND1 genes and NFE2L2 genes. According to the detection result, the recurrence-free survival rate and recurrence risk of the laryngeal squamous cell carcinoma patient are rapidly and accurately evaluated at low cost, a new direction is provided for prognosis evaluation of the laryngeal squamous cell carcinoma patient, and a basis is provided for a subsequent treatment scheme of the patient. For example, a patient with high recurrence risk adopts an enhanced comprehensive treatment scheme (such as a radiotherapy and chemotherapy combined targeted treatment scheme), a patient with low recurrence risk avoids excessive treatment, and resource waste and side effects caused by invalid treatment are reduced.

The invention discloses a precise tumor chemoradiotherapy drug delivery device, which relates to the technical field of medical instruments, and comprises an injection host and a high-precision peristaltic pump mounted in the injection host, and further comprises a drug storage mechanism, a movable loosening and clamping assembly and a leakage detection assembly. During use, three independent cabin seats are arranged in the medicine storage mechanism, three medicine storage devices are clamped in the three independent cabin seats respectively, loading of three chemotherapeutic medicines can be completed in advance, frequent replacement of medicine storage cylinders is not needed, ordered infusion of the three medicines is achieved through opening and closing of a controllable communication valve in the gathering pipeline assembly, the treatment time is shortened, infusion continuity is improved, and the treatment efficiency is improved. In addition, in the medicine injection process, all the sensors detect medicine leakage, pipeline blockage, bubbles and medicine stock in real time, and precise medicine conveying is achieved. And a clamping mechanism is arranged in the module cabin body assembly, so that the medicine storage cylinder can be quickly disassembled and assembled, and the operation is simple and convenient.

The invention provides a naphthazarin compound with a structure as shown in a formula (I), or a pharmaceutically acceptable salt or a stereoisomer or a prodrug molecule or a solvate of the naphthazarin compound, a pharmaceutical composition of the naphthazarin compound, and application of the naphthazarin compound, the pharmaceutically acceptable salt or the stereoisomer or the prodrug molecule or the solvate of the naphthazarin compound. The compound can down-regulate ATM protein level in tumor cells and remarkably inhibit phosphorylation of Chk1 protein, so that activation of a DDR pathway is inhibited, proliferation of the tumor cells is inhibited, and the compound can be used as a sensitizer or an anti-tumor drug for tumor chemoradiotherapy. # imgabs0 #

The application belongs to the technical field of biotechnology, and particularly relates to a lysosome-targeting probe and a preparation method and application thereof. The structural formula of the lysosome-targeting probe is shown in formula (I). In formula (I), A is selected from an oxygen atom and a sulfur atom, R1 is selected from a hydrogen atom and an aromatic ring group, R2 is selected from a cyano group and a group shown in formula (II), R3 is selected from an aromatic ring group, and R4 is selected from a hydrogen atom and an alkyl group with a carbon atom number of 1-20. The compound of the application can specifically target lysosomes in tumor cells, emit bright fluorescence, and has a good fluorescence co-localization effect with lysosomes in tumor cells. The compound can be used for lysosome imaging, and the fluorescence intensity thereof is positively correlated with the viscosity of lysosomes in living cells such as tumor cells. The compound can be used for monitoring the viscosity change of lysosomes in living cells under various conditions. The compound can be used as a photosensitizer and a treatment sensitizer, specifically ablates tumors through photodynamic therapy (PDT), restores the sensitivity of tumor cells to radiotherapy and chemotherapy, and enhances the treatment effect of radiotherapy and chemotherapy.

Provided in the present disclosure is a strain of Lacticaseibacillus rhamnosus DY801 and an application thereof. The Lacticaseibacillus rhamnosus DY801 is deposited in the Guangdong Microbial Culture Collection Center (GDMCC) on Oct. 9, 2022, with a deposit number of GDMCC 62853. The Lacticaseibacillus rhamnosus DY801 provided by the present disclosure may inhibit oxidative stress in the intestinal tract and damage to the small intestinal villi under radiotherapy and chemotherapy conditions by producing a large amount of glutathione in order to reduce inflammatory cytokines, which is also tolerant to artificial gastric and intestinal fluids, and has no obvious toxic side effects on the human body, providing a high level of safety.

The invention relates to the technical field of traditional Chinese medicine compositions, and discloses a traditional Chinese medicine compound composition for adjuvant therapy of cancers and a preparation method thereof. Comprising the following traditional Chinese medicine components in parts by weight: 5-10 parts of scorpio, 10-20 parts of royal jelly freeze-dried powder, 5-15 parts of ginseng, 10-20 parts of rhizoma polygonati, 10-30 parts of astragalus membranaceus, 5-15 parts of dendrobium officinale, 10-20 parts of rehmannia, 5-15 parts of lucid ganoderma, 10-30 parts of oldenlandia diffusa, 10-20 parts of radix ophiopogonis, 5-15 parts of dogwood, 10-20 parts of codonopsis pilosula, 5-15 parts of liquorice, 0.1-0.5 part of selenium yeast, 5-15 parts of edible tulip, 10-20 parts of hawthorn, 5-15 parts of chrysanthemum and 10-30 parts of dandelion. And 3-10 parts of cinnamon. The scorpion, the pseudobulbus cremastrae seu pleiones and other components can directly inhibit tumor cell proliferation and induce apoptosis; the selenium yeast can scavenge free radicals and inhibit tumor angiogenesis. The royal jelly freeze-dried powder, the ginseng, the astragalus membranaceus, the lucid ganoderma and the like can activate immune cells, improve the immune monitoring ability of a body and relieve immunosuppression caused by radiotherapy and chemotherapy.

The application belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating ovarian cancer, a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following raw medicinal materials: Astragalus membranaceus (Fisch.) Bunge, Ramulus Cinnamomi, Poria cocos (Schw.) Wolf, Semen Persicae, Gynostemma pentaphyllum (Thunb.) Makino, Radix Moutan, Magnolia officinalis Rehd. et Wils., and Hirudo nipponia Whitfield. The traditional Chinese medicine composition has the effects of benefiting qi and activating blood, removing blood stasis and dredging collaterals. Therefore, the traditional Chinese medicine composition is suitable for patients after surgery or radiotherapy and chemotherapy for ovarian cancer, and is also suitable for patients who cannot tolerate surgery or radiotherapy due to poor physical condition. The traditional Chinese medicine composition has the effects of reducing tumor cell proliferation, regulating tumor immunity, reducing toxicity and increasing efficacy. In the maintenance treatment stage, the traditional Chinese medicine composition can enhance the immunity of patients, prolong the survival period of patients, and improve the life quality of patients.

The invention discloses a multi-acupoint self-adaptive electrode stimulation and chemoradiotherapy reaction relieving device, and relates to the technical field of medical instruments, the multi-acupoint self-adaptive electrode stimulation and chemoradiotherapy reaction relieving device comprises an auxiliary frame, a linkage assembly is arranged on the rear surface of the auxiliary frame, and an extraction assembly is arranged on the front surface, close to the top, of the auxiliary frame. According to the multi-acupuncture-point self-adaptive electrode stimulation and chemoradiotherapy reaction relieving device, in the treatment process of a patient, when one electrode plate body needs to be extracted to be attached to a certain acupuncture point of the body of the patient, the protective sleeve corresponding to the electrode plate body is clamped and fixed through the clamp, and then the electrode plate body is taken out to be attached to the acupuncture point of the body of the patient; the electrode slice body is rotated to the position where the pasting face is downward, the two arc-shaped positioning blocks are driven to clamp and position the protective sleeve, the specific position of the acupuncture point of a patient is found through the infrared thermal imager, the electrode slice body is accurately pasted, and therefore the work intensity of medical workers is reduced.